NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer

被引：0
|
作者：
Swain, Sandra M.
Tang, Gong
Geyer, Charles E.
Rastogi, Priya
Atkins, James Norman
Donnellan, Paul P.
Fehrenbacher, Louis
Azar, Catherine A.
Robidoux, Andre
Polikoff, Jonathan
Brufsky, Adam
Biggs, David D.
Levine, Edward A.
Zapas, John L.
Provencher, Louise
Perez, Edith A.
Paik, Soonmyung
Costantino, Joseph P.
Mamounas, Eleftherios P.
Wolmark, Norman
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, Washington, DC USA
[2] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA
[3] NSABP Biostat Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA
[5] Natl Surg Adjuvant Breast & Bowel Project, Dallas, TX USA
[6] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[7] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA
[8] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[9] Natl Surg Adjuvant Breast & Bowel Project, Goldboro, NC USA
[10] SCCC CCOP, Goldboro, NC USA
[11] All Ireland Cooperat Oncol Res Grp, Galway, Ireland
[12] Univ Hosp Galway, Galway, Ireland
[13] Natl Surg Adjuvant Breast & Bowel Project, Vallejo, CA USA
[14] Kaiser Permanente Northern Calif, Vallejo, CA USA
[15] Natl Surg Adjuvant Breast & Bowel Project, Denver, CO USA
[16] Kaiser Permanente, Denver, CO USA
[17] Natl Surg Adjuvant Breast & Bowel Project, Montreal, PQ, Canada
[18] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[19] Natl Surg Breast & Bowel Project, San Diego, CA USA
[20] Kaiser Permanente Southern Calif, San Diego, CA USA
[21] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA
[22] Natl Surg Adjuvant Breast & Bowel Project, Newark, DE USA
[23] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[24] Natl Surg Adjuvant Breast & Bowel Project, Winston Salem, NC USA
[25] Wake Forest Univ, Surg Oncol Serv, Winston Salem, NC 27109 USA
[26] Natl Surg Adjuvant Breast & Bowel Project, Baltimore, MD USA
[27] Medstar Franklin Sq Med Ctr, Baltimore, MD USA
[28] Natl Surg Adjuvant Breast & Bowel Project, Quebec City, PQ, Canada
[29] Hop St Sacrement, Ctr Hosp Affilie Univ Quebec, Quebec City, PQ, Canada
[30] Natl Surg Adjuvant Breast & Bowel Project, Jacksonville, FL USA
[31] Mayo Clin, Jacksonville, FL 32224 USA
[32] Natl Surg Adjuvant Breast & Bowel Project, Ctr Biostat, Pittsburgh, PA USA
[33] Natl Surg Adjuvant Breast & Bowel Project, Canton, OH USA
[34] Aultman Hosp, Canton, OH USA
[35] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
10.1200/jco.2012.30.18_suppl.lba1000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1000
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adriamycin & cyclophosphamide (AC) followed by docetaxel (D) versus AC followed by paclitaxel (P) in operable node positive breast cancer
    Abdel-Halim, I.
    Ei-Sadda, W.
    [J]. BREAST, 2011, 20 : S65 - S65
  • [2] Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E., Jr.
    Rastogi, Priya
    Atkins, James N.
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan A.
    Brufsky, Adam M.
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Northfelt, Donald W.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3197 - +
  • [3] Phase II randomized adjuvant trial of dose-dense docetaxel (DOC) before or after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast cancer.
    Puhalla, S.
    Young, D.
    Ottman, S.
    McVey, A.
    Kendra, K.
    Mrozek, E.
    Rhodes, C.
    Merriman, N. J.
    Knapp, M.
    Patel, T.
    Thompson, M. E.
    Maher, J. F.
    Moore, T. D.
    Shapiro, C. L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S115 - S116
  • [4] Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer
    Puhalla, Shannon
    Mrozek, Ewa
    Young, Donn
    Ottman, Susan
    McVey, Anne
    Kendra, Kari
    Merriman, Nancy J.
    Knapp, Mark
    Patel, Taral
    Thompson, Mark E.
    Maher, James F.
    Moore, Timothy D.
    Shapiro, Charles L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1691 - 1697
  • [5] Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
    Dickler, M. N.
    Traina, T.
    Panageas, K.
    Steingart, R.
    Dang, C.
    Fornier, M.
    Sugarman, S.
    Norton, L.
    Hudis, C.
    Rugo, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide:: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Fornier, MN
    Seidman, AD
    Theodoulou, M
    Moynahan, ME
    Currie, V
    Moasser, M
    Sklarin, N
    Gilewski, T
    D'Andrea, G
    Salvaggio, R
    Panageas, KS
    Norton, L
    Hudis, C
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (12) : 3934 - 3941
  • [7] A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Farley, Cindy P.
    Barton, John H.
    Peacock, Nancy W.
    Spigel, David R.
    Greco, F. Anthony
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (03) : 242 - 248
  • [8] DOSE-DENSE (DD) DOXORUBICIN AND CYCLOPHOSPHAMIDE (AC) FOLLOWED BY WEEKLY PACLITAXEL (P) WITH TRASTUZUMAB (T) AND LAPATINIB (L) IN HER2 OVEREXPRESSED/AMPLIFIED BREAST CANCER (BC): FIRST SAFETY RESULTS
    Dang, C.
    Lin, N.
    Lake, D.
    Theodoulou, M.
    Drullinsky, P.
    Gorsky, M.
    Chen, C.
    Norton, L.
    Winer, E.
    Hudis, C.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 77 - 77
  • [9] Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Dang, C. T.
    Lin, N. U.
    Lake, D.
    Dickler, M. N.
    Modi, S.
    Seidman, A. D.
    Steingart, R. M.
    Norton, L.
    Winer, E. P.
    Hudis, C. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)
    Geyer, C.
    Bryant, J.
    Romond, E.
    Tan-Chiu, E.
    Ewer, M.
    Keefe, D.
    Shannon, R.
    Yothers, G.
    Wolmark, N.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 141 - 141
12345